Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VOLTAREN ARTHRITIS PAIN vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.
Relief of pain and inflammation associated with osteoarthritis,Relief of pain and inflammation associated with rheumatoid arthritis,Relief of pain and inflammation associated with ankylosing spondylitis,Acute pain (including migraine),Dysmenorrhea
Management of moderate to moderately severe pain,Acute pain,Chronic pain
Oral: 50 mg twice daily or 75 mg twice daily for osteoarthritis; immediate-release: 50 mg three times daily for rheumatoid arthritis. Maximum daily dose: 150 mg.
1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).
Approximately 2 hours; terminal half-life may be prolonged in elderly (up to 4 hours) or hepatic impairment.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment or overdose); Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release); Clinical context: Terminal half-life of oxycodone may be prolonged in elderly or patients with renal/hepatic impairment.
Hepatic metabolism via CYP2C9; also undergoes conjugation (glucuronidation) and hydroxylation.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP450 (CYP2E1, CYP3A4) to toxic NAPQI. Oxycodone: hepatic via CYP3A4 (major) and CYP2D6 (minor) to active metabolites (noroxycodone, oxymorphone).
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Acetaminophen: renal excretion of metabolites (glucuronide 45-55%, sulfate 20-30%, cysteine and mercapturate conjugates 5-10%) and unchanged drug (<5%); Oxycodone: renal excretion of unchanged drug (approximately 10-19%) and metabolites (noroxycodone, oxymorphone, and their glucuronides) (total renal elimination ~60-87%); fecal elimination of Oxycodone is minimal (<10%).
>99% bound to albumin.
Acetaminophen: 20-30% (albumin); Oxycodone: 45-50% (albumin).
0.1–0.2 L/kg; primarily distributes to synovial fluid (concentrations up to 50% of plasma).
Acetaminophen: 0.9-1.0 L/kg (suggests distribution into total body water); Oxycodone: 2.6-4.0 L/kg (suggests extensive tissue distribution).
Oral: 100% (immediate-release); topical: approximately 6% systemic absorption.
Acetaminophen: Oral 85-90%; Oxycodone: Oral 60-87% (first-pass metabolism), Rectal (oxycodone suppository) ~60-80%.
GFR >30 m L/min: no adjustment. GFR 10-30 m L/min: dose reduction to 50 mg once daily or avoid use. GFR <10 m L/min: contraindicated.
e GFR 30-60 m L/min: start with 50% of usual dose, increase cautiously; e GFR <30 m L/min: start with 25% of usual dose, extend dosing interval to every 8-12 hours; avoid in dialysis due to oxycodone accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 75 mg/day). Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: start with 50% of usual dose, maximum acetaminophen 2000 mg/day; Child-Pugh C: contraindicated.
For juvenile idiopathic arthritis: 1-2 mg/kg/day in 2-3 divided doses, maximum 3 mg/kg/day or 150 mg/day. For children <1 year: not recommended.
Weight-based: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg/dose) with acetaminophen 10-15 mg/kg/dose every 4-6 hours; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day).
Start at lowest effective dose (e.g., 50 mg once daily). Increase cautiously; maximum 100 mg/day. Monitor renal function and GI bleeding risk.
Start with lowest dose (e.g., half of adult dose), titrate slowly; avoid in patients with impaired renal/hepatic function or those at risk for falls; monitor for respiratory depression and constipation.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen may cause hepatotoxicity; neonatal opioid withdrawal syndrome; CYP3A4 interaction with benzodiazepines or other CNS depressants.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure and edema; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; ophthalmic effects; hepatic effects; asthma; masking of inflammation and fever.
Addiction, abuse, misuse; respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; hepatotoxicity (acetaminophen); interactions with CNS depressants; elderly or debilitated patients; renal impairment; severe hypotension; adrenal insufficiency; use in patients with head injury.
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; pregnancy (third trimester); history of gastrointestinal bleeding or perforation related to previous NSAID therapy; active peptic ulcer disease; severe heart failure; known hypersensitivity to diclofenac or any component of the product.
Hypersensitivity to acetaminophen or oxycodone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction (e.g., paralytic ileus); severe hepatic impairment; concurrent use with MAOIs or within 14 days.
No specific food interactions with topical diclofenac. However, high-fat meals may increase systemic absorption if gel is applied over large areas; advise avoiding excessive intake of fatty foods when using large doses. Alcohol may increase risk of gastrointestinal irritation if oral NSAIDs are taken concurrently; avoid excessive alcohol consumption.
Avoid alcohol. Grapefruit juice may increase oxycodone levels; limit or avoid grapefruit products. High-fat meals may delay absorption of oxycodone. Maintain adequate hydration to prevent constipation.
First trimester: Risk of miscarriage and congenital malformations (cardiac, gastroschisis) increased; avoid use. Second trimester: Possible oligohydramnios and fetal renal impairment. Third trimester: High risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, oligohydramnios; contraindicated after 30 weeks gestation.
Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; respiratory depression at delivery. No specific human data for combination; extrapolated from individual components.
Limited excretion into breast milk (M/P ratio approximately 0.02-0.04). Considered compatible with breastfeeding due to low infant dose (<0.1% of maternal weight-adjusted dose); monitor infant for gastrointestinal effects.
Acetaminophen: Compatible; M/P ratio ~1.0 (low transfer). Oxycodone: Low levels in milk; M/P ratio ~3.6 (relative infant dose 1.7–6.3% of maternal weight-adjusted dose). Monitor infant for drowsiness, respiratory depression. Use lowest effective dose, shortest duration.
No specific pharmacokinetic dose adjustments established; avoid or use lowest effective dose for shortest duration. Increased renal clearance in pregnancy may reduce drug levels, but risks outweigh benefits; generally not recommended.
Acetaminophen: No dose adjustment needed; use lowest effective dose. Oxycodone: Pharmacokinetic changes in pregnancy include increased clearance (due to enhanced hepatic metabolism and renal blood flow) and increased volume of distribution, potentially reducing plasma concentrations. Dose may need to be increased (monitor for efficacy and avoid withdrawal); however, use lowest effective dose to minimize neonatal risks. Consider non-opioid alternatives.
Voltaren Arthritis Pain (diclofenac sodium topical gel 1%) is indicated for osteoarthritis of superficial joints (e.g., hands, knees). Apply 2-4 g per affected joint four times daily. Maximum total daily dose is 32 g for upper extremities and 16 g for lower extremities. Avoid contact with eyes and mucous membranes. Use for at least 4 weeks to assess efficacy. Do not apply to open wounds or infected areas. Concurrent use of oral NSAIDs increases risk of GI and renal toxicity; consider cumulative dose. Monitor for signs of local site reactions or systemic effects, especially in elderly or those with renal impairment.
Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen intake should not exceed 4000 mg. Oxycodone has high abuse potential; consider prescribing naloxone for patients at risk of opioid overdose. Avoid concurrent use of other CNS depressants. Use with caution in elderly or renally impaired patients.
Apply the gel to clean, dry skin only on the painful joint. Do not use on broken skin, cuts, or infections.,Use the enclosed dosing card to measure the correct amount: 2 to 4 grams per joint, up to four times daily.,Do not exceed 32 grams per day for hands, wrists, elbows, or 16 grams per day for knees, ankles, or feet.,Wash hands immediately after applying unless treating hands; then wait 1 hour before washing.,Allow the gel to dry for several minutes before covering the area with clothing or gloves.,Avoid applying sunscreen, cosmetics, lotions, or other topical products to the treated skin.,Do not use heat (e.g., heating pad) or bandage the treated area.,Inform your doctor if you have a history of stomach ulcers, bleeding, kidney disease, or are taking blood thinners.,Stop use and contact your doctor if you develop a rash, swelling, or worsening pain in the treated area.,Keep out of reach of children and pets. In case of accidental ingestion, seek medical attention.
Do not exceed 4000 mg of acetaminophen per day from all sources.,This medication can cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol while taking this medication.,Take exactly as prescribed; do not crush, chew, or break extended-release tablets.,Store securely out of reach of children and dispose of unused medication properly.,Seek emergency medical attention if you experience difficulty breathing, severe drowsiness, or signs of an allergic reaction.
No interactions on record
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VOLTAREN ARTHRITIS PAIN vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE, answered by our medical review team.
VOLTAREN ARTHRITIS PAIN is a NSAID (Topical) that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VOLTAREN ARTHRITIS PAIN and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VOLTAREN ARTHRITIS PAIN is: Oral: 50 mg twice daily or 75 mg twice daily for osteoarthritis; immediate-release: 50 mg three times daily for rheumatoid arthritis. Maximum daily dose: 150 mg.. The standard adult dose of ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is: 1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VOLTAREN ARTHRITIS PAIN and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VOLTAREN ARTHRITIS PAIN is classified as Category C. First trimester: Risk of miscarriage and congenital malformations (cardiac, gastroschisis) increased; avoid use. Second trimester: Possible oligohydramnios and fetal renal impairme. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human stud. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.